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Background: Pneumonia is responsible for a large proportion of hospital admissions and antibiotic utilization.
Physician adherence to evidence-based pneumonia management guidelines is poor. Antimicrobial stewardship
programs (ASPs) are an effective intervention to mitigate against unwarranted variation from these guidelines.
Despite this benefit, ASPs have not been shown to reduce the length of stay of hospitalized patients with
pneumonia. In immune-competent adult patients admitted to a hospital ward with a diagnosis of community-acquired
pneumonia, does a multi-faceted ASP utilizing prospective chart audit and feedback reduce the length of stay,
compared with usual care, without increasing the risk of death or readmission 30 days after discharge from
hospital?
Methods/Design: Starting on 1 April 2013, all consecutive immune-competent adult patients (>18 years old)
admitted to a hospital ward with a positive febrile respiratory illness screening questionnaire and a diagnosis of
pneumonia by the attending physician will be eligible for inclusion in this non-randomized study. All eligible
patients who fulfill the ASP review criteria will undergo a prospective chart audit, followed by an ASP
recommendation provided to the attending physician. The attending physician is responsible for implementing
or rejecting the ASP recommendation. This is a modified stepped-wedge design with a baseline data collection
period of 3 months, followed by non-random sequential introduction of the ASP intervention on each of four
hospital wards in a single community-based, academic-affiliated 339-bed acute-care hospital in Barrie, ON,
Canada. The primary outcome measure is hospital length of stay; secondary outcome measures include days
and duration of antibiotic therapy, and inadvertent adverse outcomes of 30 day post-discharge mortality and
hospital readmission rates. Differences in outcome measures will be assessed using extended Cox regression
analysis. Time to ASP intervention is included as a time-dependent covariate in the final model, to account for
time-dependent bias.
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Discussion: By designing a pragmatic clinical trial with unique design and analytic features, we not only expect
to demonstrate the effectiveness of a real-world ASP, but also provide a model for program evaluation that can
be used more broadly to improve patient safety and quality of care.
Trial registration: ClinicalTrials.gov NCT02264756.
Keywords: antimicrobial stewardship, community-acquired pneumonia, length of stay, natural experiment,
pragmatic clinical trial, stepped-wedge design, time-dependent biasBackground
Community-acquired pneumonia
Community-acquired pneumonia (CAP) is defined as an
acute infection of the lower respiratory tract in patients
residing outside of hospital for 90 days or longer before
presentation [1]. Residents of long-term care homes or
nursing homes are frequently diagnosed as having a
microbiologically variant form of CAP, but there is little
evidence to support this classification system [2, 3].
There is no gold-standard diagnostic test or set of cri-
teria for CAP [4], so the diagnosis is made clinically
using a constellation of clinical signs and symptoms and
diagnostic tests.
In Ontario, pneumonia is the leading cause of death
from bacterial infections and accounts for over 18,000
years of life lost annually owing to premature mortality
[5]. Pneumonia accounts for the majority of antibiotic
utilization in both hospital and outpatient settings [6, 7].
Evidence-based guidelines for the diagnosis and manage-
ment of pneumonia are available to physicians [1, 8–12].
Adherence to these evidence-based guidelines is associ-
ated with reductions in both mortality and antibiotic
utilization [13–18].
Antimicrobial stewardship
Antimicrobial stewardship is defined as any intervention
that minimizes unwarranted variation in antimicrobial
utilization from evidence-based best practice with the
intent of improving patient safety and quality of care
[19]. ‘Unwarranted’ refers to the absence of patient- or
disease-specific reasons to justify practice variation from
evidence-based practice standards. Antimicrobial steward-
ship can be operationalized in many different ways, but
prospective audit and feedback (persuasive approach) and
restricted antimicrobial prescribing policies (restrictive ap-
proach) appear to be the most efficacious interventions to
achieve the goals of antimicrobial stewardship [19, 20].
Antimicrobial stewardship programs (ASPs) have demon-
strated efficacy in improving antimicrobial prescription
and reducing rates of hospital-acquired infections [20].
Antimicrobial stewardship programs directed at CAP pa-
tients have demonstrated reductions in mortality [15, 21],
but have failed to demonstrate reductions in length of stay
[20]. Of note, the study by Fine et al. [22] used a clusterrandomized controlled trial design to examine the impact
of an ASP on length of hospital stay in CAP patients. This
was the only study to model length of stay as a time-
to-event occurrence; differences between the length of
stay in intervention and control groups were assessed
by survival analysis. The intervention consisted of a
prospective chart audit starting on day 3 of hospitalization
and physician feedback in the form of a recommendation
suggesting the optimal timing of conversion from intra-
venous to oral antibiotics. The intervention was modeled
as a time-invariant dichotomous variable in the final
model, despite the fact that the timing of the recommen-
dation varied by up to 7 days from the time of enrollment.
The hazard ratio for discharge was 1.16 (95 % confidence
interval, 0.97–1.38) for the intervention group, suggesting
a non-significant reduction in length of stay of 16 %. It is
unknown whether this hazard ratio would have reached
statistical significance if the intervention was modeled
as a time-dependent covariate in the final model, as
unaccounted-for time-dependent bias might have di-
luted the final intervention effect point estimate [23].
Research question
In immune-competent adult patients admitted to a hos-
pital ward with a diagnosis of CAP, does a multi-faceted
ASP utilizing prospective chart audit and feedback re-
duce the length of hospital stay and days and duration
of antimicrobial therapy, compared with usual care,
without increasing the risk of death or readmission 30
days after discharge from hospital?
Methods/Design
Setting
All participants will be admitted patients of the Royal
Victoria Regional Health Centre, a 339-bed community-
based, university-affiliated, acute-care hospital located in
Barrie, Ontario, Canada. This centre is the only hospital
serving the 128,000 residents of Barrie. Access to acute
medical care for Ontario residents, including all hospital
services, is publicly funded by the Ministry of Health
and Long-Term Care, the provincial agency responsible
for funding and oversight of Ontario’s Medicare system.
All patients enrolled in the study will be admitted to
one of four medical wards. All study patients will be
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medical ward is controlled by bed allocation, a non-
medical administrative service within the hospital that is
responsible for patient flow and assigning patient care.
Hospitalists are not assigned to any one specific medical
ward, but provide care across all medical wards.
Population
Starting 1 April 2013, all consecutive adult patients
(≥18 years old) with the following inclusion criteria will
be screened for enrollment in the study [5]:
1. Screen positive for febrile respiratory illness on
admission to hospital [24], and
2. Diagnosed with pneumonia by the admitting
physician (acute exacerbations of chronic obstructive
lung disease are considered within the definition of
pneumonia for the purposes of this study, as they
are commonly treated with the same antimicrobial
regimens as patients with pneumonia), and
3. Admitted to a medical ward.
All patients who meet these criteria will be eligible for
the intervention except for those with the following
exclusion criteria [5]:
1. Hospitalized for ≥48 consecutive hours in the
preceding 3 months, or
2. Receiving immunosuppressants (defined as ≥40 mg
prednisone daily, or steroid equivalent, for ≥2 weeks
preceding hospitalization or any other
immunosuppressant used for systemic illness or to
prevent transplant rejection), or
3. Neutropenic (defined as a polymorphonuclear count
≤0.5 × 109 cells/l) for any cause, or
4. Immunocompromised (defined as having leukemia,
lymphoma, HIV with CD4 cell count ≤200,
splenectomy or receiving cytotoxic chemotherapy), or
5. Admitted to high-acuity units, such as intensive care
units, or
6. Require mechanical ventilation, either non-invasive
or invasive, or
7. Have a life expectancy of ≤3 months (palliative).
Intervention
All eligible patients with CAP who meet the ASP review
criteria will receive the ASP intervention (ASP-i). This
intervention consists of a prospective chart audit and
physician feedback (persuasive) approach [25]. The ASP
members who conduct all the audits and make recom-
mendations consist of a pharmacist trained in infectious
diseases (LM) and a physician trained in infectious dis-
eases (GD). All patients are reviewed by both members.
The ASP-i recommendations are guided by the InfectiousDiseases Society of America CAP guidelines [1] and the
Canadian Thoracic Society guidelines for the manage-
ment of chronic obstructive pulmonary disease [26].
The possible ASP-i recommendations are based on
those recommended by the UK National Health Service
[25] and include:
1. No change to current care
2. Discontinue antibiotics
3. Intravenous to oral conversion
4. Duration of therapy
5. Dosing change
6. Narrow or broaden spectrum of therapy.
The ASP-i recommendations are not mutually exclu-
sive. All recommendations are documented in the pa-
tient’s electronic medical record and communicated
directly to the attending physician by the ASP members.
Study design
This is a pragmatic controlled non-randomized clinical
study intended to measure the effectiveness of a ‘real-
world’ program [27]. The ASP-i will be implemented in
a modified stepped-wedge design [28]. Baseline patient
data will be collected for all enrolled patients on each of
the medical wards for the first 3 months of the study,
and then the ASP-i will be introduced to each medical
ward in a non-randomized sequential fashion in 2-
month intervals until all medical wards are exposed to
the intervention. This design was chosen for several rea-
sons; the preponderance of evidence suggests that anti-
microbial stewardship interventions are beneficial to
patient safety and quality of care [29]; there are human
resource limitations in rolling out the program simultan-
eously to all wards; and the design has the advantage of
a contemporaneous control group for comparison. The
unit of randomization in this study could have been the
four medical wards; however, randomization of the
wards was not included in the design. The allocation of
CAP patients to one of the four medical wards is con-
trolled by bed allocation, an administrative branch of the
hospital. Bed allocation was blinded to the study and the
process of patient allocation is solely dependent on bed
availability. In addition, the patients, regardless of their
ward location, were all admitted to the hospitalist ser-
vice. The hospitalist service provides coverage across all
four medical wards and has no influence on the alloca-
tion of patients to any of the wards. In essence, the
patients will be ‘naturally’ allocated to one of the four
medical wards and one of the attending hospitalists by a
bed allocation process that is blinded to the intervention,
so that the additional randomization of the wards them-
selves should provide very little benefit with respect to
minimizing selection bias. In addition, the four medical
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one of the medical wards has historically accommodated
more CAP patients than the other three. As a result, this
ward was chosen as the first ward to receive the ASP-I,
as this would ensure that the maximum number of CAP
patients would have earlier access to the ASP-i. The
ethical principle of utilitarianism was used to guide the
order of ward exposure to the ASP-i. The target of the
intervention is the most attending physician (hospital-
ist) , while the unit of analysis will be individual patient
outcomes adjusted for potential clustering effects
within hospital wards.
Outcome measures
The primary outcome measure is length of hospital stay,
measured in minutes from the documented time of ad-
mission to the documented time of discharge (or censor-
ing). These times are determined and entered into the
patient’s electronic medical record by bed allocation staff
who are blinded to the intervention. The secondary out-
come measures are days and duration of antibiotic ther-
apy. The start and stop dates corresponding to antibiotic
administration while the patient is admitted to hospital
are entered into the patient’s electronic medical record
by pharmacy assistants who are blinded to the interven-
tion. All inpatient antibiotic administration is verified
through the paper-based medical administration record
by a pharmacy assistant blinded to the intervention. The
number of days of antibiotic therapy is defined as the
total number of days of all antibiotics administered to
the patient both while in hospital and after discharge.
The duration of antibiotic therapy is defined as the num-
ber of days that the patient received antibiotics both
while in hospital and after discharge. For example, if a
patient received two antibiotics for 4 days over the same
time period, then the days of antibiotic therapy is 8 days
and the duration of antibiotic therapy is 4 days. The
relevance of collecting both days and duration of therapy
is that days of therapy is considered a valid metric for
monitoring and comparing antibiotic utilization both
within and across hospitals, whereas duration of therapy
is necessary for determining adherence with best-practice
treatment guidelines [30]. All antibiotic data from dis-
charged patients will be extracted (by LM or GD) from
the physician discharge summary and all patients will be
contacted 30 days after discharge to verify their adherence
with the prescribed antibiotic record from the discharge
summary. Other secondary outcome measures include in-
advertent adverse outcomes of readmission and mortality
30 days after discharge from hospital. Readmission to hos-
pital is determined through telephone survey with the pa-
tient and verification through the Royal Victoria Regional
Health Centre patient database. Survival is determined
through telephone survey with the patient. The status ofpatients who cannot be reached by telephone will be veri-
fied through the Ontario vital statistics registry.Participant timeline
Enrollment of patients started 1 April 2013. The study is
expected to enroll patients until 31 March 2015. All
consecutive patients who meet the inclusion criteria and
have no exclusion criteria will be eligible for the inter-
vention. The ASP-i intervention may be implemented
any time from 48 hours after admission in those
patients who meet the criteria for ASP review. All
patients who have not experienced an outcome meas-
ure at 14 days after admission will be censored from
the study. Patients who die or are transferred from the
ward (to the intensive care unit or other hospital) will
also be censored. Patients who are discharged from
hospital and are not censored will be contacted 30 days
after discharge to determine their adherence with anti-
biotic prescription (if relevant), survival status, and
readmission status.Sample size
The sample size expected for the current study is ‘fixed’
and has been previously estimated at between 400 and
500 CAP patients per calendar year [31]. The accrual
period will be 24 months. Assuming that 70 % of pa-
tients in the control arm will achieve the primary out-
come of being discharged alive from hospital, and
setting power = 0.8 and statistical significance (two-sided)
α = 0.05, the detectable ASP-i effect size is estimated to be
up to an approximately 20 % reduction in length of stay
[32]. The stpower cox command in STATA/MP 13.1 for
Mac will be used for the calculation.Recruitment
All consecutive immune-competent adult patients admitted
to a hospital ward with a diagnosis of CAP will be enrolled
in the study, to ensure maximum enrollment.Assignment of intervention
Given the ‘naturally’ blinded allocation process of pa-
tient admission to one of four medical wards, the pres-
sure to demonstrate an early impact to administrators
and the ethical principle of utilitarianism, the ASP-i will
first be implemented in the medical ward most likely to
accommodate the majority of CAP patients. The re-
mainder of the wards will be sequentially introduced
to the ASP-I in order from the ward most likely to
care for the most to that most likely to care for the
least number of CAP patients, based on historical ad-
mission patterns.
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It is not possible to blind the ASP members or the
attending physicians to the ASP-i. The ASP members
are not blinded to the outcome assessment, but this
should have minimal risk of bias, given the objective
nature of the primary and secondary outcome mea-
sures. The principal investigator is also responsible
for data analysis, given the absence of biostatistical
expertise at the hospital, the absence of funding to
support external biostatistical services, and the need
to create quarterly reports for the hospital administra-
tors, as required by the employment contract between
the Royal Victoria Regional Health Centre and the
principal investigator.
Data collection
All patient-level data will be extracted from the patients’
electronic medical records by the ASP members, using a
standardized electronic data collection form that is ac-
cessible on a portable tablet computer. The elements of
the data dictionary defining the variables and instruc-
tions for data abstraction have been preprogrammed
into each variable’s respective field and can be accessed
at the point of care by touching the field name. Other
techniques to ensure internal validity of the data include
preprogrammed data integrity constraints, such as range
checking and logical data edits and predefined value lists
in drop-down menus for the vast majority of data ele-
ments. Summary descriptive statistics for all continuous
variables will be calculated within each patient record to
permit real-time review, to identify any potential outly-
ing values. The external validity of the data will be
assessed by an external reviewer on a biannual basis
using a random sample of 10 % of the database. The
data elements that will be audited by the external re-
viewer include only those elements that are included as
either outcomes or covariates in the final statistical
model and are feasible for validation against an objective
source. Access to patient-level data is restricted to ASP
members. All patient-level data will be protected ac-
cording to the Personal Health Information Protection
Act of Ontario regulations [33].
Statistical methods
An extended Cox regression analysis that models the
ASP-i as a time-variant covariate will be used to com-
pare the primary and secondary outcome measures
between the control and intervention groups [34]. Vio-
lations of the proportional hazards assumption for
each covariate will be identified using the method of
Schoenfeld residuals combined with the graphical
method of log-log survival curve analysis [34]. Results
will be reported as hazard ratios with 95 % confidence
intervals. Patients who remain in hospital beyond 14 dayswill be administratively censored. Competing events, such
as death or transfer from a medical ward to a critical
care unit will be assumed to be non-informative condi-
tional on the covariates included in the final model
[34]. Time to ASP-i will be modeled as a time-variant
covariate in the final model to account for any time-
dependent bias [23]. The ASP-i exposure will be coded
as a dichotomous variable; 0 = no ASP-i, switching to 1
= ASP-i at the time of the ASP-i and remaining 1
throughout the remainder of the follow-up time. This
method treats a patient who has received an ASP-i as a
non-ASP-i patient prior to the intervention. Other vari-
ables known to be associated with the primary and
secondary outcome measures will also be included in
the final model [5], and include; age, sex, Charlson co-
morbidity index, CURB-65 score, time (days) to clinical
resolution, and complications from pneumonia, such as
empyema. Fixed effects of wards on the outcomes will
accounted for by including them as indicator variables
in the final model. Maturation of ASP-i effect on out-
comes over time will be adjusted by including a cat-
egorical time variable in the final model (time variable
will be defined as ‘quarter’ from start of study). A di-
chotomous variable for acceptance or rejection of the
ASP-i will be part of an interaction term with the
control/intervention group variable to permit a per-
protocol analysis. Sensitivity analysis will be done using
a competing events Cox regression model to determine
the impact of the assumption of the non-informative
nature of events, such as death and admission to an in-
tensive care unit [35].
Monitoring
The hospital administration requires quarterly reporting
of primary and secondary outcome variables. Secondary
adverse outcome measures such as mortality and readmis-
sion rates to hospital within 30 days after discharge will be
monitored in real-time by preprogrammed calculation of
relative risk ratios adjusted by the LACE score [36]. Rela-
tive risk ratios >1.2 for death or readmission at 30 days
post-hospital discharge for the intervention group will be
used to notify the hospital administration that an inadvert-
ent adverse event might be due to the intervention, and
an external safety monitoring committee of the Hospital
Pharmacy and Therapeutics committee will be responsible
for auditing the program. This relative risk ratio was
chosen by the hospital administration as a reporting
trigger.
Research ethics
The study has received approval from the research
ethics board of the Royal Victoria Regional Health Centre
(in an unnumbered research ethics board document enti-
tled ‘Intervention study of the impact of an antimicrobial
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tients admitted to Royal Victoria Regional Health Centre
with a diagnosis of community-acquired pneumonia
(CAP) using a before-and-after quasi-experimental study
with a control group’.) A waiver of informed consent was
approved by the research ethics board because of the na-
ture of the pragmatic clinical trial [37, 38], based on the
minimal risk of harm to patients and the fact that any
ASP recommendation that is implemented will have
required that the attending physician receive informed
consent from the patient as per the usual process of care.
A waiver for informed consent was also granted to the
ASP members to contact the patients by phone 30 days
after discharge, in order to ensure the safety of the pro-
gram with respect to its impact on readmission and mor-
tality rates. Any protocol amendments or violations will
be reported to the research ethics board for review.
Discussion
Pragmatic clinical trials are designed to embed research
into practice, to reduce the delay observed in translating
clinical research into practice [39]. Pragmatic clinical trials
not only produce results that are immediately relevant to
patients and stakeholders, but these results emerge from
methodologically reliable designs [40]. Despite these
qualities, pragmatic clinical trials made up only 2 % of
registered clinical trials in ClinicalTrials.gov in the cal-
endar year 2013 (search terms: ‘pragmatic* or prac-
tical* or comparative-effective*’ versus ‘clinical trials’
(accessed July 6, 2014)). In Canada, peer-reviewed re-
search funding agencies dispensed over 45,500 grants
and awards totalling more than $12 billion from 1999/
2000 to 2013/2014, but only 480 of these totalling
$118 million were used to support pragmatic clinical
trials (Canadian Research Information System, http://
webapps.cihr-irsc.gc.ca/cris/search; search terms: ‘prag-
matic, practical, comparative-effectiveness’ (accessed July
6, 2014)). None of these grants and awards were used to
support community-based pragmatic clinical trials. While
this trial is designed to demonstrate the effectiveness of an
ASP-i designed to reduce the length of hospital stay of
CAP patients, an important finding that has yet to be pub-
lished, it is also meant to demonstrate both the feasibility
and value of research that is conceived and conducted by
community-based healthcare providers. Given that more
than 60 % of all inpatients in Ontario are admitted to
community-based hospitals [41], it is essential that
community-based healthcare providers are invited to
suggest locally relevant research studies that are eligible
for dedicated peer-reviewed funding opportunities. This
study is intended to be an example and guide for those
community-based healthcare providers interested in
contributing to improving their healthcare programs
and systems by using pragmatic clinical trial designs.There are no previous studies examining the effect-
iveness of a prospective audit and feedback ASP-i on
important patient outcomes that account for time-
dependent bias. In general, these ASP-interventions are
time-dependent interventions that have been incor-
rectly included as time-invariant covariates in statistical
models. From an epidemiological perspective, these
ASP-interventions are not present at the time of hos-
pital admission but are ‘acquired’ at some time after ad-
mission to hospital. In the biased analysis, patients who
are exposed to an ASP-i are analyzed as though the
ASP-i had occurred at the time of hospital admission,
thereby increasing the denominator of the length-of-
stay hazard. The result of this mis-specification is a re-
duction in the length-of-stay hazard in the ASP-i group.
The resultant length-of-stay hazard ratio will be biased
and closer to 1, suggesting the absence of any beneficial
ASP-i effect [23]. This study is the first to account for
time-dependent bias by including ASP-i as a time-
variant covariate in the final statistical model.
This study has several challenges to its internal and ex-
ternal validity. First, the absence of medical ward
randomization could introduce selection bias. However,
the allocation of patients to the ward and their medical
provider is determined through a ‘natural’ allocation
process that is blinded to the study, thus minimizing this
potential source of bias. Secondly, the ASP members are
not blinded to the intervention, outcome measure assess-
ment, or data analysis. However, the likelihood of intro-
ducing bias is minimal because the primary and
secondary outcome measures are stringently defined and
objective. Thirdly, the risk of contamination is significant
given that the hospitalists provide coverage across the
four medical wards. It is conceivable that their behaviour
will change over time as they become conditioned to the
ASP-i and that this behaviour change might then precede
the ASP-i as the study evolves over the 2 year period.
The consequence of this contamination would be to bias
the outcome hazard ratios toward a value of 1 or no
ASP-i effect. However, a recent Cochrane review of the
impact of audit and feedback on physician behaviour
demonstrated only a 4.3 % (interquartile range, 0.5 % to
16 %) absolute increase in adherence with best practice
[42], suggesting that the risk of contamination in this
study might be small given the inherent resistance of
physicians to changes in behaviour. In addition, the rate
of ASP-i consults per month (defined as the ratio of the
number of ASP-i consults to the number of eligible pa-
tients) will be modeled as time series data, and an assess-
ment using regression analysis and the Durbin alternative
test will be used to detect any serial correlation between
the previous months’ ASP-i and the subsequent rate of
ASP-i consults. Evidence of serial correlation between
preceding ASP-i and subsequent rates of ASP-i consults
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ination in this study might simply represent that the ASP
was able to effectively change physician behaviour in a posi-
tive manner; a desirable impact for patient care, albeit with
some undesirable effects on exposure-outcome evalu-
ation. Fourth, the timing of the ASP-i at ≥48 hours after
admission restricts the option of recommending earlier
conversions from intravenous to oral antibiotics in eli-
gible patients. Previous studies have suggested that
earlier conversions might reduce length of stay [31, 43].
If the causal mechanism for reducing length of stay is
through this earlier conversion, then this study might
not be able to detect this ASP-i effect. As a single hos-
pital site study, the applicability of the results to other
hospitals and programs is unknown. However, a multi-
site study using the same design, intervention, and
analysis is currently being planned. Submissions of the
proposal have been made to each participating hospi-
tal’s research ethics board. The anticipated start date of
this multi-site study is 1 May 2015.
We believe that the ASP-i will lead to shorter lengths
of hospital stay for CAP patients and reduced adminis-
tration of unnecessary antibiotics, both of which should
result in reduced rates of hospital-acquired complica-
tions and reduced healthcare costs. In addition, this
study offers a model for community-based healthcare
providers to design and conduct a pragmatic clinical trial
for the purpose of programmatic evaluation. By involv-
ing community-based hospitalized patients and their
healthcare providers in translating research into practice,
access to improvements in our healthcare system will fi-
nally be more equitably distributed and shared.
Trial status
The study has enrolled 582 patients. The study will con-
tinue to enroll patients until 31 March 2015.
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